Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …
of the options for the treatment of excess weight and recent advances have revolutionized …
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: a pathophysiological update
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
Long-term efficacy and safety of anti-obesity treatment: where do we stand?
YJ Tak, SY Lee - Current obesity reports, 2021 - Springer
Abstract Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism
and causes cardiovascular diseases. Although behavioral modification is important for the …
and causes cardiovascular diseases. Although behavioral modification is important for the …
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …
[HTML][HTML] Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …
Brown adipose tissue—a translational perspective
Brown adipose tissue (BAT) displays the unique capacity to generate heat through
uncoupled oxidative phosphorylation that makes it a very attractive therapeutic target for …
uncoupled oxidative phosphorylation that makes it a very attractive therapeutic target for …
Incretin hormones and type 2 diabetes
abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …